Perspective Therapeutics, Inc.（CATX）财务数据CATXPerspective Therapeutics, Inc.

Perspective Therapeutics, Inc. (CATX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Brachytherapy, accounting for 87.4% of total sales, equivalent to $1.91M. Another important revenue stream is Drug Operations. Understanding this composition is critical for investors evaluating how CATX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Perspective Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -36120.99%, while the net margin is -33312.35%. These profitability ratios, combined with a Return on Equity (ROE) of -39.57%, provide a clear picture of how effectively CATX converts its operational activities into shareholder value.

In the context of the broader market, CATX competes directly with industry leaders such as INGN and INCR. With a market capitalization of $142.69M, it holds a significant position in the sector. When comparing efficiency, CATX's gross margin of 100.00% stands against INGN's 45.51% and INCR's 0.34%. Such benchmarking helps identify whether Perspective Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The financial performance shows a concerning trend with a net income loss of -26,786,000 USD in Q2 2026 and a gross margin of 100%, indicating that while the company does not have direct costs associated with its revenue, it is still not profitable overall. The current ratio is 6.61, suggesting good short-term liquidity, but the overall financial health is poor due to consistent losses.